Cyclophosphamide protection in NZB/NZW disease. Mechanisms and therapeutic regimens.
暂无分享,去创建一个
[1] D. Katz,et al. Induction of tolerance to nucleic acid determinants by administration of a complex of nucleoside D-glutamic acid and D-lysine (D-GL). , 1975, Journal of immunology.
[2] C. K. Osterland,et al. Modification of NZB-NZW F1 autoimmune disease by development of tolerance to DNA. , 1974, Journal of immunology.
[3] B. Stollar,et al. Prevention of Murine Lupus Nephritis by Carrier-Dependent Induction of Immunologic Tolerance to Denatured DNA , 1973, Science.
[4] G. Bole,et al. Augmented incidence of neoplasia in NZB-NZW mice treated with long-term cyclophosphamide. , 1973, The Journal of laboratory and clinical medicine.
[5] H. J. Goldsmith,et al. Cyclophosphamide therapy and sterility. , 1972, Lancet.
[6] A. Steinberg,et al. Therapeutic studies in NZB-W mice. II. Relative efficacy of azathioprine, cyclophosphamide and methylprednisolone. , 1972, Arthritis and rheumatism.
[7] A. Steinberg,et al. Cytotoxic drugs in treatment of nonmalignant diseases. , 1972, Annals of internal medicine.
[8] B. Siegel,et al. Influence of Cytoxan and Poly I·C on Early Antinuclear Antibody Responses in New Zealand Black Mice 1 , 1972, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[9] V. Beral,et al. Insensitivity of respiratory centre to carbon dioxide in the Enga people of New Guinea. , 1971, Lancet.
[10] A. Steinberg,et al. Cyclophosphamide in lupus nephritis: a controlled trial. , 1971, Annals of internal medicine.
[11] H. Kunkel,et al. ANTIBODIES TO POLYNUCLEOTIDES IN HUMAN SERA: ANTIGENIC SPECIFICITY AND RELATION TO DISEASE , 1971, The Journal of experimental medicine.
[12] J. Miller,et al. Multiple late complications of therapy with cyclophosphamide, including ovarian destruction. , 1971, The American journal of medicine.
[13] A. Steinberg,et al. The role of NZB-NZW F1 thymus in experimental tolerance and auto-immunity. , 1970, Arthritis and rheumatism.
[14] G. L. Floersheim. A comparative study of the effects of anti-tumour and immunosuppressive drugs on antibody-forming and erythropoietic cells. , 1970, Clinical and experimental immunology.
[15] Sharp Gc,et al. Autoantibodies: friend or foe? , 1970 .
[16] T. Casey. Immunosuppression by cyclophosphamide in NZB X NZW mice with lupus nephritis. , 1968, Blood.
[17] A. Aisenberg,et al. The thymus and recovery from cyclophosphamide-induced tolerance to sheep erythrocytes. , 1968 .
[18] J. D. Hicks,et al. Cyclophosphamide treatment of renal disease in (NZB x NZW) F1 hybrid mice. , 1968, Lancet.
[19] P. Lambert,et al. PATHOGENESIS OF THE GLOMERULONEPHRITIS OF NZB/W MICE , 1968, The Journal of experimental medicine.
[20] F. Dietrich. The immune response to heterologous red cells in mice. , 1966, Immunology.
[21] J. Marmur. A procedure for the isolation of deoxyribonucleic acid from micro-organisms , 1961 .
[22] P. Schur,et al. Development of reticulum cell sarcoma during cyclophosphamide therapy. , 1974, Arthritis and rheumatism.
[23] A. Steinberg. Efficacy of immunosuppressive drugs in rheumatic diseases. , 1973, Arthritis and rheumatism.
[24] E. Hurd. Immunosuppressive and antiinflammatory properties of cyclophosphamide, azathioprine and methotrexate. , 1973, Arthritis and rheumatism.
[25] J. Decker. Toxicity of immunosuppressive drugs in man. , 1973, Arthritis and rheumatism.
[26] H. Paulus,et al. Immunosuppressive therapy: guidelines for drug dosage. Depression of bone marrow granulocyte reserves in systemic lupus erythematosus. , 1972, Arthritis and rheumatism.
[27] R. Schwartz,et al. On the mechanism of immunological tolerance in cyclophosphamide-treated mice. , 1970, Clinical and experimental immunology.